Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
29.14
+0.34 (1.18%)
Jul 28, 2026, 11:57 AM EDT - Market open
Genmab Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Genmab stock has a consensus rating of "Strong Buy" and an average price target of $37.96. The average 1-year stock price forecast is 30.27% higher than the current stock price, while the lowest is $32 (+9.81%) and the highest is $43 (+47.56%).
Price Target: $37.96 (+30.27%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Genmab stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 9 | 9 | 9 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Reiterates $33 | Hold | Reiterates | $33 | +13.25% | Jul 23, 2026 |
| TD Cowen | TD Cowen | Buy Upgrades $32 → $43 | Buy | Upgrades | $32 → $43 | +47.56% | Jul 22, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $40 | Buy | Reiterates | $40 | +37.27% | Jul 13, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 30, 2026 |
Financial Forecast
Revenue This Year
4.47B
from 3.72B
Increased by 20.21%
Revenue Next Year
5.25B
from 4.47B
Increased by 17.46%
EPS This Year
1.19
from 1.77
Decreased by -32.73%
EPS Next Year
1.69
from 1.19
Increased by 42.13%
EPS and Forward PE are based on non-GAAP adjusted numbers.